Maura McCormack
- http://

All that click counting is well and good. And growing page views are an advertisers delight. But how much time are people really spending looking at various web sites?

Jay Meattle at Compete.com has a great breakdown of where people spent most of their time on the web in December 2006. Some of the results are surprising.

Twenty domains account for fully 39% of time spent online. MySpace.com (a division of the News Corporation, NYSE:NWS ) was the big winner, taking a lion's share of 11.9% viewing time (27,999,906,051 minutes) followed by Yahoo! Inc.(NASDAQ:YHOO) with 19,898,123,587 minutes. According to these figures, 11.9% of ALL TIME online was spent at MySpace.com!

The big surprise is Google, Inc. (NASDAQ:GOOG). It came in only fifth with 2.1% (4,959,635,138 minutes). The figures for YouTube (#12 with 1,327,25, 263 minutes) were separate, but even if you add them together they don't get close to Yahoo.

Also, some sad(to me) appearances in the top 20: Neopets.com at #18, accounting for 0.3% of viewing time with 593,851,415 minutes, and adultfriendfinder .com at #19 for 0.2% of viewing time with 575,584,893 minutes.

Maybe Christmas is a lonelier time for some.

The General Electric Company's (NYSE:GE) Plastics deal will be huge. Tom Taulli recently posted on the Wall Street Journal's coverage of GE's club policy concerning any potential deal.

But PEHub's Dan Primack says that the Journal's got it all wrong. He says that GE's bankers for the deal, Goldman Sachs Group (NYSE:GS), "could care less" about any Department of Justice inquiry into collusion of private equity pals.

Goldman told only four firms that they couldn't play together: Blackstone, Apollo Management, Bain Capital and KKR. Those four firms, however, may still team up with other private equity firms as long as they get approval from Goldman to share the confidential documents of the deal. It's standard operating procedure on big deals for Goldman, which wants as many players in the sandbox as possible. It's just trying to keep the biggest kids on the block on separate teams.

So it's business as usual for the sake of competition, not collusion.

This post is written as part of AOL Money & Finance's Best & Worst 2006. If you think this was the dumbest moment in business, cast your vote.

Bausch & Lomb's (NYSE:BOL) stock still hasn't recovered from its bungled management of rumored product contamination earlier this year.

I say rumored because the FDA never found conclusive evidence that the company's MoistureLoc solution directly caused serious fungal eye infections. But the company's slow-motion response to a growing chorus of suspicious infections cost it dearly in the end. The product was pulled from the Asian market in February, and the American market on April 13. A worldwide recall was issued May 15.

The company's stance was that there was nothing found in the various FDA inspections. But it was like talking into a gale force wind. The circumstantial evidence piled up. February 15 saw the stock at $70; by May 12 it traded at around $40.

It's hard for management to get in front of a worldwide recall when the company's culpability remains in question. But that's just what Bausch & Lomb needed to do, and didn't. Doing the right thing too slowly can be as damaging as doing nothing at all, particularly when it comes to consumer health products. It's peoples' eyes for goodness sake, get it off the shelves everywhere! The solve-the-mystery-later approach came a little too late.

In November of 2005, Bausch & Lomb had a share price of $82. Today it's at about $49. Yet the best the FDA could come up with in its most recent spanking of the company was to cite it for failure to report foreign infections -- the jury is still out on the actual cause.

Steve Wynn's accidental ripping of Picasso's Le Reve ("The Dream") is the year's most expensive errant elbow. Fellow collector and hedge fund billionaire Steve Cohen has a bit more space for Damien Hirst's refreshed shark since the deal to sell him the Picasso for $139 million abruptly ended as Wynn stuck his elbow into the painting.

Wynn suffers from an eye disease called retinitis pigmentosa, which impairs his peripheral vision, and this may have contributed to the unfortunate poke as he showed off the painting to a group of friends in September.

Wynn paid $48.4 million for the painting in 1997, so a two-inch tear is a $90.6 million loss. Nora Ephron quotes Wynn saying "This has nothing to do with money. The money means nothing to me," moments after putting his elbow through the famous painting. I guess you can file that under 'H': for 'How the rich are different.'

But it's probably true. So no tears for Mr. Vegas.

Wynn's been a billionaire since 2004. And it's a good thing since the repair is estimated to cost $85,000. Pocket change! His wife Elaine has been quoted as saying she considers this "a sign" that they should keep the painting, so keep it they will. In addition, Wynn Resorts (NASDAQ:WYNN) recently announced a $6 per share dividend. The extra $8 million or so should help ease the pain of not selling the most expensive painting ever.

Steve Wynn has at least acquired some great nicknames: "Cubist Killer "(NY Post) and "billionaire goofball "(BoingBoing.net). This is also a cautionary note to those of us who tend to talk with our hands -- it could end up costing you.